Free Trial
NASDAQ:EVOK

Evoke Pharma Q2 2023 Earnings Report

Evoke Pharma logo
$5.70 +0.25 (+4.59%)
Closing price 04:00 PM Eastern
Extended Trading
$5.58 -0.12 (-2.11%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Evoke Pharma EPS Results

Actual EPS
-$6.72
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Evoke Pharma Revenue Results

Actual Revenue
$1.13 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Evoke Pharma Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Thursday, August 10, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Evoke Pharma's Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Monday, August 11, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Evoke Pharma Earnings Headlines

Green Light for These Stocks
Guess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... becoming the largest shareholder in a critical mineral company tied to national security. Former hedge fund manager Whitney Tilson believes this is just the start of a sweeping plan to unlock trillions in hidden federal assets... from oil-rich land to rare earths and energy reserves. He says this could mark the beginning of the largest wealth transfer in modern U.S. history, and has identified the surprising areas where you could benefit.
See More Evoke Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Evoke Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evoke Pharma and other key companies, straight to your email.

About Evoke Pharma

Evoke Pharma (NASDAQ:EVOK), a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

View Evoke Pharma Profile

More Earnings Resources from MarketBeat